TXG
10x Genomics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
65.40
▲ 1.53 (2.40%)
MARKET · —
Price
Open
64.44
Prev close
63.87
Day high
65.47
Day low
61.75
Volume
3.14M
Market cap
$8.48B
P/E (TTM)
—
52W range
11.16 – 65.47
Trailing performance
Returnvs SPY
1W
+16.10%
+17.5%
1M
+35.50%
+31.8%
3M
+163.86%
+160.8%
6M
+244.92%
+233.8%
YTD
+299.26%
+287.0%
1Y
+387.43%
+367.4%
3Y
+36.01%
-38.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$8.48B
Enterprise value$8.01B
Revenue (TTM)$616.91M
Gross profit$432.53M
EBITDA$-41.20M
Net income$-75.13M
EPS (TTM)$-0.61
Free cash flow$179.66M
Total cash$552.03M
Total debt$78.80M
Book value / share$6.31
Shares outstanding120.21M
Float118.18M
Short % of float17.59%
Dividend yield—
Beta (5Y)2.04
Valuation & profitability ratios
Trailing P/E—
Forward P/E320.27
PEG ratio—
Price / sales—
Price / book10.32
EV / revenue12.99
EV / EBITDA-194.45
Gross margin70.11%
Operating margin-15.20%
Profit margin-12.18%
Return on equity-9.40%
Return on assets-5.05%
Debt / equity9.55
Current ratio5.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $642.82M | $610.78M | $618.73M | $516.41M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$43.54M | -$182.63M | -$255.10M | -$166.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$43.54M | -$182.63M | -$255.10M | -$166.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.02 | 0.03 | +258.4% |
| Mar 2026 | -0.06 | 0.07 | +219.2% |
| Dec 2025 | -0.04 | 0.07 | +276.3% |
| Sep 2025 | -0.07 | -0.02 | +67.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 3 | $147.16M | -1.2% |
| Next quarter | -0.00 | 3 | $171.57M | +3.3% |
| Current year | 0.11 | 2 | $619.93M | -3.6% |
| Next year | 0.20 | 3 | $679.33M | +9.6% |
Analyst targets & ownership
Mean target$49.54
High target$65.00
Low target$40.00
Implied upside-24.25%
Analyst count13
ConsensusBUY
Strong buy / Buy1 / 5
Hold10
Sell / Strong sell0 / 0
Held by insiders1.60%
Held by institutions112.02%
Institutions holding513
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+220.00K
Net buying
Buy transactions
10
409.01K shares
Sell transactions
14
189.02K shares
Net transactions
+24
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
2.08M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | TEICHMANN SARAH A. Director |
SELL | 7.55K | $432.28K | Direct |
| Aug 11, 26 | STUELPNAGEL JOHN R Director |
SELL | 20.00K | $1.16M | Direct |
| Jun 22, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 30.00K | $1.03M | Direct |
| Jun 16, 26 | SULIMAN SHEHNAAZ Director |
SELL | 5.72K | $186.76K | Direct |
| Jun 4, 26 | MATEO ALAN V. Director |
STOCK | 8.83K | $0 | Direct |
| Jun 4, 26 | KOSARAJU SRIDHAR Director |
STOCK | 8.83K | $0 | Direct |
| Jun 4, 26 | SULIMAN SHEHNAAZ Director |
STOCK | 8.83K | $0 | Direct |
| Jun 4, 26 | TEICHMANN SARAH A. Director |
STOCK | 8.83K | $0 | Direct |
| Jun 4, 26 | POPOVITS KIMBERLY J Director |
STOCK | 8.83K | $0 | Direct |
| Jun 4, 26 | STUELPNAGEL JOHN R Director |
STOCK | 8.83K | $0 | Direct |
| May 26, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 28.89K | $709.06K | Direct |
| May 22, 26 | TAICH ADAM Chief Financial Officer |
SELL | 15.10K | $369.02K | Direct |
| May 22, 26 | HINDSON BENJAMIN J President |
SELL | 11.60K | $283.40K | Direct |
| Apr 14, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 5.00K | $122.78K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HINDSON BENJAMIN J |
President | 502.00K | Sale |
KOSARAJU SRIDHAR |
Director | 68.28K | Stock Award(Grant) |
MATEO ALAN V. |
Director | 85.88K | Stock Award(Grant) |
POPOVITS KIMBERLY J |
Director | 37.45K | Stock Award(Grant) |
SAXONOV SERGE WILSON |
Chief Executive Officer | 1.39M | Sale |
STUELPNAGEL JOHN R |
Director | 348.44K | Sale |
SULIMAN SHEHNAAZ |
Director | 31.72K | Sale |
TAICH ADAM |
Chief Financial Officer | 379.90K | Sale |
TEICHMANN SARAH A. |
Director | 28.06K | Sale |
Moving averages & technicals
SMA 10
59.38
+10.13% from price
SMA 20
53.49
+21.74% from price
SMA 50
44.77
+45.46% from price
SMA 100
34.48
+89.66% from price
SMA 200
26.56
+145.18% from price
EMA 12
58.00
+12.75% from price
EMA 26
52.75
+23.98% from price
EMA 50
46.36
+41.08% from price
RSI (14)
74.0
Overbought
MACD (12,26,9)
5.25
Hist 0.75
ATR (14)
4.06
6.24% of price
Realised vol 30D
77.9%
Annualised
Bollinger upper
66.30
20, 2σ
Bollinger lower
40.68
20, 2σ
50 / 200 cross
Golden
44.77 vs 26.56
Trend bias
Above 200
+145.18%
Risk profile
Beta vs SPY
2.29
More volatile than market
Correlation to SPY
0.41
Loosely linked
Realised vol 30D
77.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-28.0%
Peak to trough
Max drawdown 5Y
-96.3%
Peak to trough
ATR 14
4.06
6.24% of price
Beta (reported)
2.04
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.20
Put-heavy session
Put / call open interest
1.16
Positioning, not flow
Max pain
55.00
-15.5% from spot
ATM implied vol
75.1%
Nearest strike to spot
Skew (10% OTM)
+0.3%
Puts bid over calls
Call volume
93
Contracts, this expiry
Put volume
112
Contracts, this expiry
Heaviest call OI
60.00
323 contracts
Heaviest put OI
55.00
399 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform
Insider Monkey · 4d ago
10x Genomics Insider Sold Shares Worth $432,279, According to a Recent SEC Filing
MT Newswires · 5d ago
10x Genomics (TXG) Could Be 35% Above Fair Value Following 2026 Outlook Lift
Simply Wall St. · 6d ago
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call
StockStory · 7d ago
1 High-Flying Stock to Own for Decades and 2 We Question
StockStory · 8d ago
10x Genomics (TXG) Q2 2026 Earnings Call Transcript
Motley Fool · 8d ago
10x Genomics Insider Sold Shares Worth $1,155,055, According to a Recent SEC Filing
MT Newswires · 9d ago
1 Unpopular Stock That Deserves Some Love and 2 That Underwhelm
StockStory · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.